Healthcare is entering a new era, and oncology is at its centre. Today, cancer specialists face rising patient volumes, expanding treatment options, and endless administrative demands. Amid this pressure, Helsinki-based Gosta Labs has raised €7.5 million in seed funding to scale its AI-powered operating system, designed specifically for complex medical fields such as oncology.
Led by Voima Ventures, with participation from COR Group, the Aho family, Reaktor, and several angel investors, the round brings Gosta Labs’ total funding close to €10 million since its launch. The startup aims to modernise how clinicians capture, manage, and act on clinical data throughout the patient journey.
Cancer treatment has become increasingly intricate, with millions of new cases expected globally in the coming decades. Clinicians often struggle with fragmented digital systems and hours of manual documentation each day. Gosta Labs is tackling this by building an AI operating system that structures clinical data in real time during each patient visit.
Instead of leaving oncologists buried in paperwork, the platform automatically generates clinical notes, visualises patient progress, and highlights critical clinical parameters tied to international treatment guidelines. This ensures consistency while freeing clinicians to focus on the patient rather than the interface.
Real-World Results Already Emerging
Early findings shared at the ESMO 2025 Congress show promising outcomes. Oncologists using Gosta’s AI assistant completed follow-up documentation in under two minutes, thanks to automated note generation and integrated classification tools that assess toxicity levels and performance status. These capabilities reduce administrative load and accelerate decision-making when it matters most.
Founded in 2023 by Lauri Sippola and Henri Viertolahti, the team behind Kaiku Health (later acquired by Elekta), Gosta Labs brings together AI researchers, medtech executives, and oncology leaders. Their experience in building regulated, globally deployed healthcare technologies provides a strong foundation for expanding into international cancer care systems.
With fresh funding secured, Gosta Labs plans to deepen its AI capabilities, strengthen its medical-device-grade product suite, and expand adoption across oncology centres worldwide. The company’s long-term goal is clear: enable more personalised care, reduce administrative strain, and help clinicians deliver faster, more precise cancer treatment at scale.